Danaher Corporation delivered second-quarter results that beat earnings estimates, yet investors remain concerned after the company cut its full-year core revenue growth outlook and reported weaker-than-expected bioprocessing revenue. Non-GAAP adjusted earnings per share reached $1.94, above the $1.83 consensus, while revenue grew 5.5% year-over-year to $6.3 billion. However, the company lowered the upper end of its 2026 core revenue growth forecast to 4% from 6%, citing weaker respiratory testing revenue, and disclosed that over $100 million in bioprocessing revenue shifted into next year. BofA maintained a Buy rating but cut its price target to $230 from $270, noting the results were messier than expected and the stock fell 11%. Danaher raised its full-year adjusted EPS guidance to a range of $8.45 to $8.60, reflecting optimism from strong quarterly performance and the early completion of the Masimo acquisition.
Danaher CorporationCut full-year core revenue growth outlook and missed bioprocessing revenue, stock fell 11%
Masimo CorporationEarly completion of Masimo acquisition cited as positive in raised EPS guidance
Bank of America Corp